SEC Form 4 · accession 0001746282-18-000003
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pericles Calias
Officer — Chief Scientific Officer
Period of report
Jul 16, 2018
Accepted (ET)
Jul 16, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.26 | Jul 16, 2018 | A | 80,000 | A | Jul 16, 2019 | Jul 15, 2028 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1The stock options will vest 25% on July 16, 2019, and the remaining 75% of the shares subject to the stock option shall vest in 36 equal monthly installments beginning on August 16, 2019, provided the Reporting Person is then an officer of the Issuer on each such vesting date.